All In Biotech

NDA 019123 · Upsher Smith Labs

Klor-Con

Potassium Chloride · Oral

Last checked: Nov 20, 2026Latest source record: Apr 30, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1986

Apr 17, 1986

Approved uses

2

Original approval plus efficacy supplements

Registered trials

9,299

2,122 Phase 3, 968 recruiting

FAERS reports

110,575

80,896 serious, 15,665 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 1, 2026.

Potassium chloride extended-release is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. Potassium chloride extended-release is a potassium salt, indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. ( 1 )

Mechanism: The potassium ion is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle and the maintenance of normal renal function. The intracellular concentration of potassium is approximately 150 mEq to 160 mEq per liter. The normal adult plasma concentration is 3.5 mEq to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane. Potassium...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 26, 1992 Supplement 8 · Efficacy
  • Apr 17, 1986 Original approval · Type 5 - New Formulation or New Manufacturer Review
2 products under this application
  • KLOR-CON · POTASSIUM CHLORIDE 10MEQ · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB2
  • KLOR-CON · POTASSIUM CHLORIDE 8MEQ · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB2

Clinical trials

Interventional ClinicalTrials.gov studies with "Chloride" as an intervention, any sponsor and status, largest first.

All 9,299 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea8,061
  • diarrhoea8,018
  • nausea7,739
  • fatigue7,639
  • death5,524
  • pneumonia5,333
  • headache5,007
  • asthenia4,954
  • dizziness4,843
  • vomiting4,824
  • pain4,745
  • off label use4,585

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,078
20052,073
20061,676
20071,948
20082,738
20093,164
20102,846
20113,378
20124,400
20132,965
20143,542
20155,860
20166,539
20176,288
20187,063
20197,001
20206,416
20216,262
20227,176
20237,145
20247,853
20257,866
20265,292

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Klor-Con (Potassium Chloride)

2024 spending

$9.7M

Beneficiaries

29,332

59,825 claims

Per beneficiary

$330

$2.55 per unit

View as table
YearSpending
2020$12,836,107
2021$9,922,011
2022$10,154,459
2023$10,901,488
2024$9,689,568

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,091 on PubMed

Sponsor: Upsher Smith Labs

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.